Last updated: 11 March 2021 at 8:27pm EST

Bay Ltd. Nomis Net Worth




The estimated Net Worth of Bay Ltd. Nomis is at least $2.52 milliard dollars as of 9 March 2021. Bay Nomis owns over 235,238 units of Humanigen stock worth over $194,247 and over the last 4 years Bay sold HGEN stock worth over $2,517,804,576.

Bay Nomis HGEN stock SEC Form 4 insiders trading

Bay has made over 18 trades of the Humanigen stock since 2020, according to the Form 4 filled with the SEC. Most recently Bay sold 235,238 units of HGEN stock worth $3,883,779 on 9 March 2021.

The largest trade Bay's ever made was selling 300,000 units of Humanigen stock on 17 July 2020 worth over $1,500,000. On average, Bay trades about 69,263 units every 15 days since 2020. As of 9 March 2021 Bay still owns at least 5,380,799 units of Humanigen stock.

You can see the complete history of Bay Nomis stock trades at the bottom of the page.



What's Bay Nomis's mailing address?

Bay's mailing address filed with the SEC is 45 Reid Street, Hamilton, Bermuda.

Insiders trading at Humanigen

Over the last 5 years, insiders at Humanigen have traded over $2,588,252,690 worth of Humanigen stock and bought 2,107,496 units worth $5,417,461 . The most active insiders traders include Dale Cheval Holdings, Ltd.B..., Dale Black Horse Capital Ma... et Bay Ltd. Nomis. On average, Humanigen executives and independent directors trade stock every 34 days with the average trade being worth of $7,693. The most recent stock trade was executed by Dale Black Horse Capital Lp... on 18 October 2023, trading 386,350 units of HGEN stock currently worth $3,864.



What does Humanigen do?

Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of anti-inflammatory immunology and immuno-oncology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which has completed Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that is in Phase II clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which has completed pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.



What does Humanigen's logo look like?

Humanigen, Inc. logo

Complete history of Bay Nomis stock trades at Humanigen

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
9 Mar 2021 Bay Ltd. Nomis
10% propriétaire
Vente 235,238 $16.51 $3,883,779
9 Mar 2021
5,380,799
25 Feb 2021 Bay Ltd. Nomis
10% propriétaire
Vente 46,505 $19.02 $884,525
25 Feb 2021
5,616,037
22 Feb 2021 Bay Ltd. Nomis
10% propriétaire
Vente 103,220 $22.29 $2,300,774
22 Feb 2021
5,662,542
17 Feb 2021 Bay Ltd. Nomis
10% propriétaire
Vente 89,408 $22.25 $1,989,328
17 Feb 2021
5,765,762
11 Feb 2021 Bay Ltd. Nomis
10% propriétaire
Vente 16,973 $19.72 $334,708
11 Feb 2021
5,855,170
8 Feb 2021 Bay Ltd. Nomis
10% propriétaire
Vente 54,273 $21.61 $1,172,840
8 Feb 2021
5,872,143
2 Feb 2021 Bay Ltd. Nomis
10% propriétaire
Vente 73,584 $20.96 $1,542,321
2 Feb 2021
5,926,416
22 Jan 2021 Bay Ltd. Nomis
10% propriétaire
Vente 95,032 $19.87 $1,888,286
22 Jan 2021
6,070,000
19 Jan 2021 Bay Ltd. Nomis
10% propriétaire
Vente 8,500 $20.29 $172,465
19 Jan 2021
6,165,032
11 Jan 2021 Bay Ltd. Nomis
10% propriétaire
Vente 25,000 $18.67 $466,750
11 Jan 2021
6,278,532
28 Dec 2020 Bay Ltd. Nomis
10% propriétaire
Vente 500 $22.20 $11,100
28 Dec 2020
6,303,532
23 Dec 2020 Bay Ltd. Nomis
10% propriétaire
Vente 53,401 $21.24 $1,134,237
23 Dec 2020
6,304,032
22 Dec 2020 Bay Ltd. Nomis
10% propriétaire
Vente 50,000 $50,000.00 $2,500,000,000
22 Dec 2020
6,357,433
10 Aug 2020 Bay Ltd. Nomis
10% propriétaire
Vente 17,100 $5.04 $86,184
10 Aug 2020
32,662,170
28 Jul 2020 Bay Ltd. Nomis
10% propriétaire
Vente 10,000 $5.66 $56,600
28 Jul 2020
32,679,270
17 Jul 2020 Bay Ltd. Nomis
10% propriétaire
Vente 300,000 $5.00 $1,500,000
17 Jul 2020
32,689,270
30 Jun 2020 Bay Ltd. Nomis
10% propriétaire
Vente 3,000 $4.91 $14,730
30 Jun 2020
32,989,270
15 Jun 2020 Bay Ltd. Nomis
10% propriétaire
Vente 65,000 $5.63 $365,950
15 Jun 2020
32,992,270


Humanigen executives and stock owners

Humanigen executives and other stock owners filed with the SEC include: